Pivotal Study of the Velocityâ„¢ pAVF System (NCT07153939) | Clinical Trial Compass
RecruitingNot Applicable
Pivotal Study of the Velocityâ„¢ pAVF System
United States126 participantsStarted 2025-10-21
Plain-language summary
This study will evaluate the Velocity Percutaneous Arteriovenous Fistula (pAVF) System, a new minimally invasive method for creating dialysis access. People with kidney failure often require dialysis, which depends on having a reliable arteriovenous fistula (AVF). Traditionally, AVFs are created with surgery, but surgery can involve incisions, longer recovery, and sometimes additional procedures before the AVF can be used.
The Velocity System is designed to create an AVF through a small puncture in the skin using a catheter-based approach, without open surgery. This pivotal study will assess how safe the procedure is and how well it works for patients who need dialysis.
The study will take place at multiple centers in the United States and will enroll adults with kidney failure who are candidates for fistula creation. Participants will undergo the Velocity procedure and then be followed closely with exams, ultrasounds, and dialysis assessments for up to five years.
Taking part is voluntary. Patients may benefit from a less invasive approach to dialysis access, but the main goal is to collect information that could improve future care for people with kidney failure.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. ESRD requiring hemodialysis access or CKD with anticipated need for hemodialysis within 6 months
✕. Cephalic vein diameter \< 2.5 mm at any point from the CPV to the axillary vein
✕. Central venous occlusion ipsilateral of the study extremity
✕. Severe calcification of the radial artery that significantly impairs ultrasound visualization (e.g., acoustic shadowing) and thus precludes safe or accurate device deployment.
✕. Evidence of active systemic infections or localized to the procedure access site within the past 7 days